Menu Search
Equities

Medipharm Labs Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MLZ:FRA

Medipharm Labs Corp

Actions
  • Price (EUR)0.0368
  • Today's Change-0.002 / -5.15%
  • Shares traded838.00
  • 1 Year change-15.98%
  • Beta0.7782
Data delayed at least 15 minutes, as of Feb 10 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MediPharm Labs Corp. is a Canada-based pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. It develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The Company cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The Company also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.

  • Revenue in CAD (TTM)46.10m
  • Net income in CAD-8.03m
  • Incorporated2017
  • Employees161.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.